RxDoctor Payments Data

Clara Kamath-Wood, MD

Family Medicine · Roseville, MINPI 1548377328

Payments from drug & device makers

$1,138in general payments, 2019–2025

Across 50 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$251
  • Amgen$118
  • Medtronic$115
  • Novo Nordisk$104
  • Lilly USA, LLC$95
  • Astellas Pharma US Inc$89
  • plus $366 from 7 others

What the payments were for

  • Food & beverage$1,04992%
  • Education$898%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,138 in reported general payments places this provider in the 70th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$140,921
Medicare patients
285
Services billed
2,704

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide76$124,569
JardianceEmpagliflozin107$114,276
EliquisApixaban71$76,766
JanuviaSitagliptin Phosphate62$75,298
MounjaroTirzepatide58$73,302
XareltoRivaroxaban54$64,351
TrulicityDulaglutide17$28,311
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$27,691
JanumetSitagliptin Phos/Metformin Hcl28$19,239
Spiriva RespimatTiotropium Bromide12$14,179
FarxigaDapagliflozin Propanediol15$14,164
Breo ElliptaFluticasone/Vilanterol27$13,821
MyrbetriqMirabegron15$13,611
Atorvastatin Calcium620$8,312
SymbicortBudesonide/Formoterol Fumarate14$7,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$41$128,455119 claims
Novo NordiskOzempic$104$124,56976 claims
Lilly USA, LLCMounjaro, Trulicity$95$101,61375 claims
PfizerEliquis, Premarin$75$81,51982 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$88$45,69473 claims
AstraZenecaFarxiga, Symbicort$30$21,21229 claims
Astellas Pharma US IncMyrbetriq$89$13,61115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →